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Background: Viral infections during pregnancy can pose serious threats to mother and fetus from the time of
conception to the time of delivery. These lead to congenital defects, spontaneous abortion and even death. The
definitive diagnosis and management of pregnancy-related viral infections may be challenging especially in less
resourced countries.
Case presentation: We present clinical and laboratory responses to the diagnosis and management of three cases
of fulminant hepatitis secondary to Hepatitis E viral infection in pregnancy.
Case 1 was a 31-year-old Ghanaian woman who presented with a week’s history of passing dark urine as well as
yellowish discoloration of the eyes. She subsequently developed fulminant hepatitis secondary to Hepatitis E viral
infection, spontaneously aborted at 24 weeks of gestation and later died.
Case 2 was also a 31-year-old Ghanaian woman who was admitted with a four-day history of jaundice. She had low
grade fever, but no history of abdominal pain, haematuria, pale stool or pruritus. She next developed fulminant
hepatitis secondary to Hepatitis E viral infection. However, she did not miscarry but died at 28 weeks of gestation.
Case 3 was a 17-year-old Ghanaian woman who was referred to the tertiary health facility on account of jaundice
and anaemia. She had delivered a live male infant at maturity of 32 weeks but noticed she was jaundiced and had
a presentation of active disease 3 days prior to delivery. The baby was icteric at birth and on evaluation, had
elevated bilirubin (mixed type) with normal liver enzymes. Hepatitis E virus infection was confirmed in both mother
and baby. However, the jaundice and the hepatomegaly resolved in mother and baby after 5 and 12 days
respectively.
Conclusion: To the best of our knowledge, these are the first documented cases of fatal fulminant hepatic failures
resulting from HEV infection in Ghana.
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Hepatitis E virus (HEV) infection is a recognised cause
of human viral disease presenting as an acute hepatitis
after an incubation period of 8-10 weeks with a clinical
illness resembling other forms of acute viral hepatitis
[1]. Transmission is primarily through the faeco-oral
route; usually from contaminated water. The disease is
usually self-limiting and has a low case-fatality rate 0.1%
in men and non-pregnant women [1]. The mortality rate
is however severe, often leading to fulminant hepatic* Correspondence: kbonney@noguchi.mimcom.org
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reproduction in any medium, provided the orfailure (FHF) and death in up to 30% of cases in HEV-
infected pregnant women [2].
The seroprevalence of HEV infection amongst preg-
nant women in Accra, Ghana, has been found to be as
high as 29% [3]. There is no or limited screening for
anti-HEV antibodies for pregnant women during routine
reproductive health programmes in Ghana. Public and
most private health institutions however screen for
antibodies to hepatitis B virus (HBV) and hepatitis C
virus (HCV) in pregnant women on suspicion of viral
hepatitis in Ghana [3]. Therefore the diagnosis of HEV
infection in pregnant women could be delayed or mis-
diagnosed with a possible fatal outcome if the disease
runs a fulminant course.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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light the preponderance of HEV in a less-resourced
country and the devastating effect it poses to pregnant
woman.
The aim of the present case series is to present our ex-
perience with FHF in three patients who had active dis-
ease in Ghana and also facilitate the urgency in the
establishment of appropriate routine laboratory diagno-
sis to enhance treatment.
Case presentation
Case 1
A 31 year old primigravida at 24 weeks gestation who
was admitted in July, 2010 with over a week’s history of
passing dark urine and yellowish discoloration of the
eyes. She had developed fever (temperature >38°C),
chills, headache and weakness by the time of her admis-
sion and was thought to have intravascular haemolysis
of unknown aetiology. She had been treated for labora-
tory confirmed malaria at 10 weeks and subsequently
started on intermittent preventive treatment. Fever
(temperature >38°C) persisted, became anaemic (Hb of
8.7 g/dL) and jaundiced and started passing dark urine.
No definite cause was identified after various investiga-
tions were done: blood film was negative for malaria
parasites. Her sickling status was negative and she was
negative for HBV and HCV. Glucose-6-phosphate de-
hydrogenase (G6PD) levels were normal. The disease
progressively worsened; became very lethargic, deeply
jaundiced and febrile and developed bilateral pitting
pedal oedema up to the knee level. A differential diagno-
sis of haemorrhagic fever was entertained after she
developed sub-conjunctival haemorrhages. Further la-
boratory investigations were performed. She had a mis-
carriage after the second day of admission at 24 weeks
gestation and died on the third day.
Laboratory investigations for molecular testing with
Reverse transcription – Polymerase chain reaction (RT-
PCR) assay, specific for yellow fever virus [4] performed
were negative. Further molecular analysis performed
with an assay based on the publication; ‘A novel real-
time PCR system for simultaneous detection of human
viruses in clinical samples with uncertain aetiology’ [5]
revealed a positive RNA for HEV infection.
The results of preliminary laboratory investigations
done were: haemoglobin of 7.4 g/dL; white blood cell
count - 4.0×109per L; platelet count - 191×109per and
the erythrocyte sedimentation rate (ESR) was 28 mm/hr.
A peripheral blood smear done for malaria parasites was
negative. The Clotting profile showed an activated partial
thromboplastin time (aPTT) of 132.0 seconds (27.0-43.0s)
and INR of 3.63 (1.00-1.25). Liver function tests results
were out of range (Table 1). The results for both HBV and
HCV with the real time RT-PCR assay by Katano et al [5]were negative. Serological testing revealed no antibodies
that are both immunoglobulin G (IgG) and immunoglobu-
lin M (IgM) for viral hepatitis E, B and C.
Case 2
A 31-year-old gravid 5 para 3 with one previous termin-
ation of pregnancy was admitted with a 28 weeks old
pregnancy and a four-day history of jaundice with low
grade fever (37.7°C). She had no previous history of
blood transfusion, jaundice or contact with a jaundiced
patient. Clinical and biochemical examinations were
performed. Obstetric and general abdominal ultrasounds
showed a normal and viable intra-uterine fetus at
28 weeks, 4 days gestation. Laboratory results obtained
showed normal haemogram, sickling test was negative
and no malaria parasites were identified. Test performed
for HBV and HCV revealed no anti-HBV or anti-HCV
IgG and IgM antibodies. The liver function test (LFT)
results were severely deranged (Table 1).
The patient’s clinical condition remained quite stable
until she started spiking temperature on the fifth day of
admission. The temperature was 39.0°C and examination
revealed left renal angle tenderness. Two days into the
parenteral antibiotic therapy the patient continued to
spike temperature and the jaundice began to deepen
with the production of dark urine. Further molecular
and biochemical tests were performed. A positive result
for HEV with the molecular test assay described above
for case 1 was revealed.
After a week of admission the patient was found to be
febrile (T = 39°C), tachypnoeic with respiratory rate of 60
cycles/minute and signs of consolidation of the left mid-
dle lung zones. Diagnosis was reviewed to include septi-
caemia secondary to left lobar pneumonia and urinary
tract infection and possible severe malaria. The clotting
profile showed INR of 4.2 and aPTT of 111.4 secs (refer-
ence range: 26-36 secs). She developed signs of hepatic
encephalopathy and was started on hepatic failure re-
gime. She was transfused with fresh frozen plasma in
preparation for induction of labour, but she died on the
eighth day before the labour induction could be started.
Case 3
A 17-year-old primipara was admitted on account of
jaundice and anaemia. She had delivered a live male in-
fant weighing 2.3 kg at a maturity of 32 weeks, a day be-
fore. The baby was icteric at birth and on evaluation,
had elevated bilirubin (mixed type) with normal liver
enzymes. She had noticed the jaundice 3 days prior to
delivery, but it worsened after the delivery and she there-
fore reported back to the medical facility. On direct
questioning she had a low grade fever, chills and had
vomited once at the onset of the jaundice. There was no
change in her bowel habits or the colour of her urine.
Table 1 Liver function tests results
Test Patients value [14,15] Ref. range (Unit)
Case 1 Case 2 Case 3
Day 1 Day 12
Total Protein 61 61.3 68 73 60 - 78 (g/L)
Albumin 16 32.4 27 31 35 - 55 (g/L)
Globulin 27.6 28.9 - - 23 - 35 (g/L)
Alkaline Phosphatase (ALP) 94 379 472 215 42 - 98 (U/L)
Gamma Glutamyl Transpeptidase (GGT) 46 100.7 17 22 5 - 40 (U/L)
Alanine Transaminase (ALT) 609 557 50 13 7 - 56 (U/L)
Aspartate Transaminase (AST) 1460 1327 80 21 6 - 34 (IU/L)
Direct (conjugated) Bilirubin 170 40.5 17 11.7 0.0 - 5 (μmol/L)
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diced person. On examination her temperature was 36.8°C,
chest clinically clear and no abnormality with her cardio-
vascular system; the blood pressure was 90/50 mmHg. The
liver was enlarged, 5 cm below the costal margin with a
span of 15 cm, but not tender. There was no ascites. The
spleen and two kidneys were not palpable. A diagnosis of
acute viral hepatitis and malaria with intravascular haema-
lysis were made for both mother and baby and were admit-
ted separately. HEV infection was confirmed in both
mother and baby after admission with the molecular assay
used in the two cases above. The jaundice and the hepato-
megaly resolved in mother and baby after 5 and 12 days re-
spectively. The HEV-infected baby had serial clinical,
serological and virological evaluation. Liver tests settled to
normal levels by 8 weeks. HEV RNA which was detected at
birth was not detectable by 3 weeks. IgM anti-HEV anti-
bodies, reactive at birth persisted for 4 weeks but did not
lose IgG anti-HEV antibodies over the observation period
of three months (Figure 1).
Discussion
To our knowledge, these are the first documented cases
of fatal fulminant hepatic failures (FHF) resulting from
HEV infection in Ghana. Hepatitis E virus infection had
hitherto been an unknown cause of jaundice in Ghana.
The first case had complained of general malaise and
pruritus about 8 weeks prior to developing clinical jaun-
dice. Platelet count was in the normal range and her
erythrocyte sedimentation rate (ESR), a non-specific
measure of inflammation, was relatively high. The ratio
of AST/ALT used sometimes in differentiating the
causes of liver damage [6] was greater than 2. This is
usually indicative of alcoholic hepatitis [7,8] and not
viral hepatitis, in which case the ratio would have been
less than 1. Case one neither drank alcohol nor smoked
cigarettes. Liver function tests done at the time showed
mild elevation of direct bilirubin and liver transaminases.
This early elevation in bilirubin probably suggested HEVinfection since physiological jaundice developed later. In
a study by Patra, S. et al., it was found that death from
FHF has been seen to be more common with HEV-
infected pregnant women, or have worse foetal out-
comes than did pregnant women with jaundice and
acute viral hepatitis caused by other hepatitis viruses [9].
This finding is consistent with our observation in the
first two cases. Furthermore, it has been established that
HEV-infected pregnant women in the second and third
trimester develop FHF with the mortality in the second
trimester around 20% and reaches up to 45% in the third
trimester [10]. This finding corroborates with our obser-
vation in that the first two fatal cases were HEV-infected
pregnant women in their second trimester.
It has been previously reported that a high proportion
of HEV-infected pregnant women develop FHF which is
mostly fatal as we observed with these three cases. In a re-
port of an HEV epidemic, 22% of pregnant women with
acute viral hepatitis developed FHF, compared with 0% of
non-pregnant women and 2.8% of men [10]. Other studies
documented the development of FHF in 32% to 69% of
HEV-infected pregnant women with acute viral hepatitis
in sporadic settings [11]. Reasons that seem likely for the
high frequency and severity of FHF in HEV-infected preg-
nant women are the diminished cellular immunity and
high levels of steroid hormones which influence hepatitis
E virus replication during pregnancy [12].
In our third case vertical transmission of HEV was
observed. Vertically transmitted HEV infection is known
to cause acute hepatitis in neonates but the clinical
course and duration of viraemia is not known [13]. The
survival and the clearance of HEV in the baby in our
third case demonstrate that HEV in neonates is self-
limiting and does not run a chronic or prolong clinical
course. This observation is consistent with a study by
Khuroo, M.S et al., in which HEV-infected neonates at
birth survived with the infection cleared [13]. The sever-
ity of HEV infection in the mother and baby may be
linked to each other. Data from a study suggested that
for 
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Figure 1 Time series of the events by date of occurrence in the three case reports of fatal hepatitis E viral infection in pregnant
women in Ghana: (a) case 1 was a 31-year-old woman with a week’s history of dark urine and yellowish discoloration of the eyes.
She was subsequently diagnosed of Hepatitis E viral infection, spontaneously aborted at 24 weeks of gestation and later died; (b) case 2, also a
31-year-old who was admitted with a four-day history of jaundice. She had low grade fever, but no history of abdominal pain, haematuria, pale
stool or pruritus. Later diagnosed of Hepatitis E viral infection, did not miscarry but died at 28 weeks of gestation; (c) case 3, a 17-year-old woman
who was referred to the tertiary health facility on account of jaundice and anaemia. She had delivered a live male infant at maturity of 32 weeks
but noticed she was jaundiced and had a presentation of active disease 3 days prior to delivery. The baby was icteric at birth and hepatitis E
virus infection was confirmed in both mother and baby. However, the jaundice and the hepatomegaly resolved in mother and baby after 5 and
12 days respectively.
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fection and provides a clear relationship between FHF of
the fetus and mother [14].
Routine laboratory investigations for HEV and other
hepatotropic viruses apart from HBV and HCV in
health institutions in less-resourced countries has been
a challenge. There is a likelihood of missing out on or
misdiagnosing such cases in health institutions in less-
resourced countries where there is low index of suspi-
cion for HEV. Usually in such instances, Yellow Fever
virus, which is also a hepatotropic virus, is suspected
and queried as in our first case. The diagnosis of the
second and the third cases were facilitated by the
knowledge of the existence of fulminant HEV infection
in the country and where to get diagnosis having
excluded HBV and HCV infections.
HEV infection is considered an important public
health concern in most developing and industrializedcountries for causing water borne outbreaks and spor-
adic hepatitis because of poor sanitary conditions. There
is no specific treatment available for Hepatitis E Virus
infection. Recombinant vaccines are being developed
and may be particularly useful for travellers to disease-
endemic areas and for pregnant women [15]. Ensuring a
clean drinking water supply remains the best preventive
strategy, however, incorporating screening for HEV in
reproductive health programmes could be vital for early
detection and reduction of maternal mortality due to
acute viral hepatitis.
Conclusion
Although the cases reported here are few, two deaths in
three HEV infections in pregnancy are very high (case
fatality rate of 67%). Further investigations from other
parts of the country and other places of similar settings
are necessary to generate data which will guide the
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